Tobramycin

證據等級: L5

預測適應症: 10 個

Tobramycin: From Bacterial Infections to Exposure Keratitis

One-Sentence Summary

Tobramycin is an aminoglycoside antibiotic with well-established bactericidal activity against Gram-negative organisms, historically used in the treatment of serious bacterial infections including pneumonia, septicemia, and urinary tract infections. The TxGNN model predicts it may be effective for Exposure Keratitis, with 2 clinical trials and 7 publications retrieved in this evidence review — though both trials are only indirectly related to this specific indication. The mechanistic basis is plausible (secondary bacterial infection prevention on a compromised corneal surface), but dedicated clinical evidence is currently absent.

Quick Overview

Item	Content
Original Indication	Serious Gram-negative bacterial infections (pneumonia, septicemia, UTI; no Philippines registration found)
Predicted New Indication	Exposure Keratitis
TxGNN Prediction Score	99.93%
Evidence Level	L4
Philippines Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Tobramycin is an aminoglycoside antibiotic — its bactericidal efficacy against serious Gram-negative infections, particularly Pseudomonas aeruginosa, has been established for decades across multiple infection sites, and mechanistically may be applicable to ocular surface infections.

Exposure keratitis (lagophthalmos-related keratopathy) develops when incomplete eyelid closure causes chronic corneal desiccation and epithelial breakdown. This damaged surface is highly vulnerable to secondary bacterial colonisation, with Pseudomonas aeruginosa and Staphylococcus aureus being the most common pathogens encountered. Tobramycin ophthalmic preparations carry demonstrably low MICs against both organisms, making prophylactic or therapeutic use mechanistically logical. The case of bacterial keratitis in a vegetative-state patient with lagophthalmos (PMID 34987857) directly illustrates this clinical scenario.

A meaningful safety signal complicates this prediction: an in vitro study (PMID 2707046) showed that tobramycin — alongside other aminoglycosides — inhibits corneal epithelial cell proliferation in a concentration- and time-dependent manner. Applying a cytotoxic agent to an already-compromised corneal epithelium introduces genuine risk, and no clinical trial has yet directly evaluated this trade-off in the exposure keratitis population. Validation in a controlled setting is therefore a prerequisite before proceeding.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06200727	NA	Unknown	170	Platelet-rich fibrin (PRF) membrane for ophthalmic diseases including corneal ulcer and glaucoma; tobramycin is not the investigational agent — relevance to tobramycin + exposure keratitis is indirect at best
NCT05313828	N/A	Unknown	40	Various treatment modalities for HSV dendritic keratitis; tobramycin, if included, would serve only as an adjunctive antibacterial agent rather than a primary study drug

Note: Neither trial directly evaluates tobramycin for exposure keratitis. Both are included as the closest available evidence; they do not constitute direct clinical support for this indication.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2707046	1989	In Vitro Study	Current Eye Research	Tobramycin and three other aminoglycosides tested on rabbit corneal epithelial cell cultures; concentration- and duration-dependent cytotoxicity observed — important safety signal for topical ophthalmic use
17228760	2006	In Vitro / Pharmacodynamic Study	Nippon Ganka Gakkai Zasshi	MIC and post-antibiotic effect of antibiotic eyedrops against infectious keratitis isolates from Japanese national surveillance; tobramycin included among comparators
34987857	2021	Case Report	Oxford Medical Case Reports	MDR Shewanella algae bacterial keratitis in a vegetative-state patient unable to close his eyes (lagophthalmos); demonstrates how exposure-type corneal compromise leads to secondary bacterial keratitis
12861116	2003	Case Report	Eye & Contact Lens	Bilateral MRSA keratitis following photorefractive keratectomy; underscores the Gram-positive pathogen dimension of post-procedural/compromised corneal infections
11581057	2001	Case Report	Ophthalmology	First reported contact lens-related Bacillus cereus keratitis with confirmed genetic identity between corneal and lens case isolates
33847093	2021	Retrospective Cohort	Polish Journal of Veterinary Sciences	Feline ocular toxoplasmosis (60 cases); limited direct relevance to human exposure keratitis but tobramycin cited within the treatment protocol
14574976	2003	Case Report	Eye Science	Paracentral corneal dellen in Graves ophthalmopathy — an exposure-type corneal complication mechanistically similar to lagophthalmos-related exposure keratitis; tobramycin used as part of ocular surface management

Safety Considerations

Please refer to the package insert for safety information.

Specific concern identified from literature: PMID 2707046 documents aminoglycoside-induced corneal epithelial cytotoxicity in vitro. In the context of exposure keratitis — where the epithelium is already compromised — prolonged topical tobramycin use may delay epithelial healing. This risk should be explicitly evaluated in any future clinical study design.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for tobramycin in exposure keratitis is currently limited to indirect case reports and an in vitro cytotoxicity study (L4); no dedicated prospective trial exists, and a biologically plausible harm signal (aminoglycoside epithelial toxicity) has not been clinically resolved. This combination — absent positive clinical data plus an unresolved safety question — does not yet support active development or repurposing pursuit.

To proceed, the following is needed:

Retrieve full mechanism of action data from DrugBank (DG002, classified as High severity)
Obtain Philippines FDA package insert for approved warnings and contraindications (DG001, Blocking severity) — currently prevents completion of the S1 safety screen
Drug interaction profile (DDI query returned no results; independent verification recommended)
Prospective clinical study specifically evaluating topical tobramycin in exposure keratitis patients with documented secondary bacterial infection risk
Comparative safety data on short-term versus prolonged topical aminoglycoside use on damaged corneal epithelium
Assessment of alternative topical antibiotics (e.g., fluoroquinolones) with superior corneal safety profiles as comparators

Broader context note: While exposure keratitis ranks first in TxGNN predictions for this evidence pack, the strongest overall clinical evidence for tobramycin repurposing lies in post-bacterial disorder (rank 5, L1) — corresponding to inhaled tobramycin for Pseudomonas aeruginosa management in cystic fibrosis and non-CF bronchiectasis, where multiple completed Phase 3 RCTs exist and tobramycin inhalation solution (TOBI®) holds regulatory approval in multiple jurisdictions. Decision-makers evaluating this candidate should weigh the full prediction landscape before prioritising resources.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.